Potentials of Chenpi on Metabolic Syndrome: A Review
Article information
Abstract
Objectives
Metabolic Syndrome (MetS) is strongly related with central obesity, hypertriglyceridemia, low high-density lipoprotein-cholesterol (HDL-C), hyperglycemia, and hypertension. This study reviewed the potential of Chenpi in treatment of MetS through amelioration of co-related diseases, such as diabetes mellitus, hyperlipidemia, obesity, hepatic steatosis, and inflammation.
Methods
Six electronic databases (Oriental Medicine Advanced Searching Integrated System (OASIS), Korean Traditional Knowledge Portal, Korea Institute of Oriental Medicine (KIOM), Research Information Sharing Service (RISS), PubMed, and Embase) were used to search for in vitro, in vivo, and clinical research that discusses the potential effects of Chenpi (Citrus unshiu Markovich, Citrus reticulata Blanco) on diabetes mellitus, hyperlipidemia, obesity, hepatic steatosis, and inflammation.
Results
This review suggests the potential of Chenpi as a candidate for the treatment of metabolic syndrome through improvement of co-related diabetes, hyperlipidemia, obesity, hepatic steatosis, and inflammation. However, comparison of the results of each study was limited by a lack of quantification of the experimental materials.
I. Introduction
Metabolic syndrome (MetS), also named as syndrome X, can be diagnosed when more than three symptoms exist out of following five pathological conditions ; central obesity, hypertriglyceridemia, low high density lipoprotein-cholesterol (HDL-c), hyperglycemia or hypertension (HTN)1. As sedentary lifestyle and over-nutrition became more common in many developed countries, the MetS has become epidemic2. The global prevalence of MetS is hard to measure, but it can be estimated by the incidence of obesity and type 2 diabetes (T2DM). Years between 1998 and 2007, the prevalence of MetS in Korean population had recorded 31.3%, and the most common pathological condition was dyslipidemia3. On 2012, the domestic prevalence of MetS recorded 28.8% for population over 30 years old, based on 2007-2010 National Health and Nutrition Survey4.
The diagnose of MetS leads to increased episodes of cardiovascular diseases (CVD), including stroke and myocardial infarction5. The risk factors that would provoke vulnerability to CVD include age, gender, family history of CVD, T2DM, insulin resistance, hyperlipidemia (HL), HTN, obesity and non-alcoholic fatty liver (NAFLD)6. Owing to multiple pathologic conditions, medicines targeting each of them are prescribed, such as hypoglycemic agents, lipid-lowering agents, antihypertensive agents, anti-platelet drugs, and weight-loss agents7. Increased risks of atherosclerotic cardiovascular disease (ASCVD) are consequences of cholesterol level imbalance8. Statins are used to reduce low density lipoprotein cholesterol (LDL-C) and total cholesterol levels, but adverse effects including musculoskeletal pain, gastrointestinal events, headache, and elevation of blood glucose and glycohemoglobin levels are present9,10. Also, as CVD is the most common risk factor of mortality in diabetes, biguanide (metformin) is commonly prescribed to MetS patients with T2DM11. However, biguanides may induce vitamin B12 deficiency, gastrointestinal disease, hemolytic anemia, hyperlactatemia, and metabolic acidosis12. Therefore, many attempts have been done to find effective therapy of MetS with less side effects.
With growing demand for natural products in MetS treatment, there had been several herbal agents reviewed about their MetS modulating effects. Some of the herbs include Satureja Species13, sylimarin14, Saffron15and Ginger16.
Chenpi, the peel of Citrus unshiu Markovich (CMP) or Citrus reticulata Blanco (CBP), has traditionally been used to treat indigestion, improve bronchial conditions, and blood circulation in east Asia17. It contains various phytochemicals such as hesperidin, naringin and nobiletin18. Among them, hesperidin, which has largest proportion, has been proven to have anti-inflammatory19, neuroprotective20, anti-cancer21, anti-diabetic, antihypertensive and antioxidant and CVD risk lowering effects22. Although several reviews about each single flavonoids are present, there are none about the herbal plant itself. As Chenpi is comprised of various phytochemicals, the effect should be differentiated from that of single constituents.
In aspects of MetS, diverse values of Chenpi have been discovered until now. These values are summarized as follows; 1. Anti-diabetic effect, 2. Lipid-lowering effect, 3. Anti-obesity effect, 4. Anti-hepatic steatosis activity, and 5. Anti-inflammatory effect.
II. Method
A. Selection of database and searching method
The purpose of this review is to discuss the effects of Chenpi on different elements of MetS, T2DM, HL, obesity and HTN, through analyzing human and experimental papers. Literature published from 2011 to date, in language of Korean and English were included. The database used for searching the literatures were Oriental Medicine Advanced Searching Integrated System (OASIS, https://oasis.kiom.re.kr/), Korean Traditional Knowledge Portal (https://www. koreantk.com/ktkp2014/), Korea Institute of Oriental Medicine (KIOM, https:// www.kiom.re.kr/), Research Information Sharing Service (RISS, http://www. riss.kr) to search for Korean literature, and PubMed (https://www.ncbi.nlm.nih.gov/pubmed), Embase (https://www.embase.com) to search for western research papers.
In domestic and English search, the keyword of ‘metabolic syndrome’, ‘syndrome X’, ‘diabetes’, ‘DM’, ‘diabetes mellitus’, ‘hyperglycemia’, ‘hyperlipidemia’, ‘dyslipidemia’, ‘lipid’, ‘obesity’, ‘NAFLD’, ‘fatty liver’, ‘hepatic steatosis’, ‘inflammation’, ‘Citrus unshiuMarkovich pericarpium’, ‘Citrus unshiuMarkovich peel’, ‘Citri reticulatae pericarpium’, ‘Citrus reticulata Blanco peel’, ‘Citrus reticulata blanco pericarpium’ were included. We combined these keywords regarding characteristic of each database. The searching procedure was done between 2021.07.01-2021.07.04.
B. Selection and exclusion
1. Selection criteria
a) In vitro/in vivo experimental study
b) Clinical study on patients with hypertension, type 2 diabetes, hyperlipidemia, obesity, or hepatic steatosis
c) Exclusive study on freeze-dried powder, water extract, ethanol extract or fermented product of Citrus unshiu Markovich peel or Citrus reticulata Blanco peel
d) Study including measurements indicating treatment effects about hypertension, type 2 diabetes, hyperlipidemia, obesity, or hepatic steatosis
e) Study written in Korean or English
2. Exclusion criteria
a) Study using combined herbal treatments
b) Study not including measurements indicating treatment effects about hypertension, type 2 diabetes, hyperlipidemia, obesity, or hepatic steatosis
C. Material selection and study analysis
We collected literatures searched in domestic and English databases, and excluded duplicating literatures based on study title, published year and authors. First step of screening was conducted based on title and abstract, following selection and exclusion criteria. Second step of screening was conducted through examining full text of previous screened records. In sequence, clinical application possibility of Chenpi was judged, and the final literature selection and analysis was conducted.
D. Data extraction
On our study, full texts of finally selected literatures were analyzed. Data about study methods, experimental model(species, number), interventions of treatment and control group (including dose and duration), positive control, measurements and results were extracted. Based on extracted data, characteristics of each literature were discussed.
III. Result
A. Literature screening
At first, 85 literatures were searched, and 50 literatures were selected after exclusion of 35 duplicating literatures. On first step of screening, titles and abstracts were examined following selection and exclusion criteria, and 14 literatures which were not related to Chenpi and MetS were excluded. On second screening, investigation of full text removed 17 literatures using treatments combined with other herbs, flavonoids or written in other language than Korean or English. As a final outcome, 19 literatures were selected on our study (Fig. 1).
B. Literature analyzing
1. Characteristics of the selected literatures
Among 19 selected literatures, there were 723-29 in vitro, 830-37 in vivo, 238,39 in vitro and in vivo, and 240,41 clinical researches. 1123,24,26-28,30,32,34,38,39,41 were published in Korea, 335-37 in United States, 327,29,40 in international journals, and 1 of each in Switzerland33, India25 and Japan31.
2. Analyze of experimental models
Among 9 in vitro studies, RIN-m5f β-cells38, HIT-15 cells39, OP9 cells23, HepG2 cells29, Human embryonic kidney 293 cells25 and NIT-1(murine pancreatic β-cells)25 were used in 1 of each studies. L6 myotubes in were used in 2 studies25,38 and 3T3-L1 cells were used in 3 studies24,27,39. Among 10 in vivo studies, C57BL/KsJ-db/db mice35 and Wistar-Hannover GALAS rats31 were used in 1 of each study. 3 studies28,36,38 selected C57BL/6 mice and 6 studies30,32-34,37,39 selected Sprague Dawely rats. In 2 clinical researches, patient with hypertriglyceridemia41 and obesity (BMI>23 kg/m2)40 were chosen.
3. Analyze of interventions
16 literatures23-35,39-41 selected Citrus unshiu Markovich peel, and 336-38 selected Citrus reticulata Blanco peel as an intervention. There were various extraction methods of Chenpi. 4 literatures23,26,37,38 used water extraction, 1024,25,28,32-36,39,41 used ethanol extraction, and 227,29 chose both water and ethanol extraction. Chenpi powder30, Chenpi juice extract40 and 1% albedo TDF extracted by method of Prosky31 were also chosen. Furthermore, 6 literatures contained positive control groups. Rosiglitazone 0.001 g/100 g diet35, estradiol (E2) 10 μg/kg33, sinetrol 0-0.5 mg/mL27,37, simvastatin 1.04 mg/kg37, resveratrol 0.1%36 and insulin 1 μM26 were used.
C. Results
1. Diabetes Mellitus
Diabetes is a worldwide health problem, with the estimated prevalence of 6.4%, globally. The total predicted increase in prevalence of T2DM from 2010 to 2030 is 54%, with estimated annual growth of 2.2%, which almost doubles the current annual growth of the global adult population42. Insulin resistance (IR) is frequently related to central obesity and CVD. Accordingly, visceral adipocytes secrete adipokines, which are the inflammatory cytokines, and they are thought to be closely concerned with the pathological conditions of MetS43. The effect of Chenpi on DM is analyzed below (Table 1).
a) Glucose-lowering effect
(a.1) In vivo
A number of in vivo studies have shown that Chenpi has glucose-lowering effect. Fasting blood glucose (FBS) level was significantly reduced by CMP ethanol extract (CMPE) 2 g per 100 g diet administered to diabetic mice (p<0.05)35 CMP water extract (CMPW) 200 or 300 mg/kg to STZ induced diabetic mice (p<0.05)38. They had tendency of being more effective dose-dependently. Bioconversed Chenpi was also studied for its anti-diabetic effects. Ethanol extract of CMP fermented by Aspergillus niger (FCMPE) 0.3%, 1% and CMPE 1% were fed ad libitum to HFD mice, and FBS was significantly lowered only in FCMPE groups (p<0.05)28. Also, FCMPE bioconversed by Aureobasidium pullulans and CMPE 0.1% or 0.5% applied to HFD rats and reduction of serum glucose was observed in all FCMPE groups and 0.5% CMPE group (p<0.05)39. By fermentation, naringin was bioconversed into naringenin. CMP water extract (CMPW) had glucose reducing effect, as well. Even though it had no significant effect in α-glucosidase inhibition, CMPW 100, 200 and 300 mg/kg administration significantly lowered glucose level in OSTT and OGTT (p<0.05). This result suggests the possibility of other hypoglycemic pathway existence, excluding α-glucosidase inhibition.
b) Insulin-stimulating effect
(b.1) In vitro
Insulin secretion stimulating effect was also tested. In vitro studies revealed insulin-promoting effect of Chenpi. CMPW 100, 200 and 300 mg/kg was applied to 15 mM glucose processed RIN-m5f β-cells, and elevation of insulin secretion in β cells was monitored (p<0.05)38. Aureobasidium pullulans bioconversed FCMPE and CMPE 0.01, 0.025 and 0.1 mg/mL applied to deoxyribose processed Hamster Islet Transformed-Tioguanine resistant clone 15 cell (HIT-T15 cell, pancreatic beta cell) stimulated insulin secretion in all groups39. In this study, FCMPE performed better effect than CMPE, especially in high dose.
General voltage-dependent K+ (Kv) channels has been proved to improve insulin secretion, membrane depolarization and Ca2+ influx in a glucose-dependent manner44-46. Among them, Kv2.1 and Kv2.2 are enriched in the pancreatic islets, and Kv2.1 is enhanced in pancreatic β-cells47. Kv2.1 modulates insulin secretion by affecting β-cells, and Kv2.2 regulates somatostatin release by affecting δ-cells. CMPE 100, 200, 500 μg/mL application to Human embryonic kidney 293 cells25 inhibited Kv2.1 channel currents in a dose-dependent manner. However, none of them had effect on Kv2.2 channel current. Also, CMPE application to NIT-1 (murine pancreatic β-cell) resulted in significant increase of insulin secretion (p<0.01). Therefore, selective inhibition of Kv2.1 without cross-inhibition of Kv2.2 would exhibit increase of insulin secretion without concern of adverse effects.
(b.2) In vivo
CMPE 2 g per 100 g diet fed to diabetic mice exhibited increase in serum insulin/glucagon ratio (p<0.05)35. CMPW 200 and 300 mg/kg were fed to STZ induced diabetic mice, and serum insulin was on the rise in both groups, dose-dependently (p<0.05)38.
c) Glucose-regulating effect
(c.1) In vitro
In vitro study of CMPW 100, 200 and 300 mg/kg applied to L6 myotubes performed elevation of glucose uptake in myotubes (p<0.05)38.
(c.2) In vivo
In vivo study of CMPE 2 g per 100 g diet administration to diabetic mice demonstrated reduction of hepatic glycogen content (p<0.05)35.
d) Glycosylated Hemoglobin, Type A1C (HbA1c) reducing effect
(d.1) In vivo
CMPW 200 and 300 mg/kg were fed to STZ induced diabetic mice, and it resulted in decrease of HbA1c index (p<0.05).
e) Amelioration of glucose tolerance
(e.1) In vivo
In HFD mice, CBP ethanol extract (CBPE) 0.2% and 0.5% induced decrease in Area Under the Receiver Operating Characteristic Curve (AUC) value of glucose tolerance test (GTT) (p<0.05) in both groups36. On a study conducted in 2017, fermented Chenpi showed decrease in AUC of Intraperitoneal Glucose Tolerance Test (IPGTT)28. Among them, only 0.3% FCMPE has significant effect, suggesting that fermented Chenpi has better effect than normal Chenpi, and it’s efficient in low dose.
f) Inhibition of gluconeogenesis
(f.1) In vitro
Protein kinase B (Akt) is one of signaling pathways that increases glucose uptake in cells. When insulin combines to insulin receptor, phosphorylation of insulin receptor substrate-1 (IRS-1) and activation of phosphatidylinositol 3-kinase regulatory (PI3KR) results in phosphorylation of Akt. Phosphorylated Akt transports glucose into intracellular space, by bumping transporter 4 (GLUT4) to membrane cell48. As well, GLUT4 is a glucose transporter that is activated by insulin, and related influx of glucose into cells49. In L6 myotubes, CMPW 50, 100, 200, 500 μg/ml up-regulated IRS-1, PIK3R and GLUT4 mRNA expression in all groups, dose-dependently. Akt mRNA expression in CMPW 100, 200 and 500 μg/ml groups were also increased, dose-dependently26.
(f.2) In vivo
There are several experiments about mRNA expression regulation related to glucose metabolism. Hepatic phosphoenol pyruvate carboxykinase (PEPCK) is an enzyme related to hepatic gluconeogenesis, which is activated in diabetic state, leading to insulin resistance50. CMPE 2 g per 100 g diet applied to diabetic mice suppressed activity of hepatic PEPCK35. Another study revealed activation of glucokinase (Gk), glucose transporter protein type 2 (Glut2) and suppression of glucose6phosphotase (G6pase) by Chenpi and fermented Chenpi medication to HFD mice28. Gk phosphorylates glucose to glucose6phosphate, and its activation leads to glycolysis and glycogen synthesis. Glut2 is an enzyme found in liver that transports glucose and G6pase is a gluconeogenic enzyme. Up-regulation of GK and Glut2 mRNA expression were superior in FCMPE groups, and down-regulation of G6pase mRNA expression was superior in CMPE group (p<0.05). Regulation of these mRNA expressions implies anti-diabetic effect of Chenpi, presenting similar property of all types of Chenpi.
g) Pancreatic beta cell protecting effect
(g.1) In vitro
Administration of FCMPE and CMPE 0.01, 0.025 and 0.1 mg/mL to deoxyribose processed HIT-T15 cell increased cell viability in all groups39.
h) Ameliorating effects in DM complication
(h.1) In vitro
In vitro study about CMPW 200 and 300 mg/kg administration to STZ induced diabetic mice reduced liver and kidney size, and lowered weight of them (p<0.05) in both groups38. It suggests that Chenpi ameliorates DM complications.
2. Hyperlipidemia
The increase of apo B-containing lipoproteins is a major risk factor of coronary artery disease51. The effect of Chenpi on hyperlipidemia (HL) is analyzed below (Table 2).
a) Serum triglyceride, cholesterol reducing effect
Low serum HDL and elevated serum TG level are convincing markers of cardiovascular diseases, and causes an increase of serum LDL level, resulting in increased cardiovascular risk52.
(a.1) In vivo
Various in vivo studies have been done to test hypolipidemic effects in HFD rats. Medication of CMPE 48.6 mg/kg (0.1%) and 241.9 mg/kg (0.5%) significantly reduced serum total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) and elevated high density lipoprotein cholesterol (HDL-C) level (p<0.05)34. Administration of Aureobasidium pullulans fermented CMPE and CMPE 0.1%, 0.5% induced reduction of serum TG, TC, LDL-C and elevation of HDL-C level (p<0.05)39. Aspergillus niger fermented CMPE 0.3% and 1% reduced serum TC level (p<0.05)28. CMPE 100 and 300 mg/kg were applied to HFD Sprague Dawley mice twice daily for 8 weeks32. Serum TC level was significantly lowered in 300 mg/kg group (p<0.001), also serum TG level in 100 (p<0.05) and 300 (p<0.001) mg/kg group. CBPE 0.2% and 0.5% lowered serum TG, LDL-C level in both groups (p<0.05), and TC level in 0.5% group (p<0.05)36. In 2020, 0.2% and 0.5% of CBPE were fed to HFD C57BL/6 mice, for 10 weeks36. Resultingly, decrease of LDL-C and TG in both groups, and TC in 0.5% group were observed, all significantly (p<0.05). CBPW 1.04 g/kg reduced serum TG, TC, LDL-C level (p<0.05) and elevated HDL-C level (p<0.05)37. As well, the efficacy of CMP powder in dyslipidemia was discovered30. Freeze-dried CMP, each 5%, 10%, 15% of HFD diet, were fed to Sprague Dawley mice for 4 weeks. Serum LDL-C was reduced in 10% group (p<0.05) and serum HDL-C was increased in 15% group (p<0.05). In both 10% and 15% groups, HDL/TC ratio was elevated, and AI was lowered, all significantly (p<0.05).
In diabetic mice, CMPE 2 g per 100 g diet significantly lowered serum TG level (p<0.05), even though there were no change in plasma TC and free fatty acid level35. In OVX rats, apply of CMPE 30, 100 and 300 mg/kg resulted in decrease of TG, TC, LDL-C level and increase of HDL-C level (p<0.05)33.
(a.2) Clinical research
Clinical research also has been done on patients with 170 mg/dL-250 mg/dL of TC level. CMPE 1200 mg medicated to 91 patients with 170 mg/dl -250 mg/dl of TC level resulted in significant reduction of serum TG level (p<0.05) and noticeable change in serum TC and HDL-C level41. Besides, there was no evidence of hepatotoxicity, as no significant differences in serum GOT, GPT, γ-glutamyl transferase (ɣ-GT) level were noted between CMPE and placebo groups. CMP juice extract 18 mg lowered serum TC (p<0.0001) and LDL-C level (p=0.011) in 118 adult patients with body mass index (BMI) over 23 kg/m240. The hypolipidemic effect of albedo, the white part of CMP, has also been tested. Albedo, which contains arabinose, galactose, xylose, and glucose, was extracted as total dietary fiber (TDF) by the method of Prosky. Wistar-Hannover GALAS rats were fed freely with diet containing 4% cellulose and 1% TDF, and their serum TG was significantly reduced (p<0.05)31.
b) Alleviation of coronary artery risk index and atherogenic index
(b.1) In vivo
Currently, atherogenic index (AI), a ratio of serum lipid concentrations, has been recommended as a biomarker for cardiovascular diseases and atherosclerosis53-55. Coronary artery risk index (CRI), is also related with MetS56.
Four in vivo studies have shown significant alleviation of AI. CMPE 241.9 mg/kg (0.5%)34, and CMP powder 10%30 each led to significant reduction of AI (p<0.05) in HFD rats. In other study, Aureobasidium pullulans fermented Chenpi has been revealed to be more effective than non-fermented Chenpi in lowering AI. In HFD rats, FCMPE 0.1% and 0.5% and CMPE 0.5% of total diet significantly lowered AI (p<0.05)39, showing that only FCMPE has significant risk-lowering effect in same dose (0.1% of total diet). Also, study about effect of Chenpi CRI and AI has been conducted. In OVX rats, CMPE 300 mg/kg significantly decreased CRI and AI (p<0.01)33. OVX rat, a model of postmenopausal symptoms, has shown bone loss caused by estrogen deficiency and lipid metabolic disturbance. It is known that CMP extract has both plasma and hepatic lipid-lowering effect through inhibition of 3-Hydroxy-3-Methyl Glutaryl-Coenzyme A (HMG-CoA) reductase activity57. The outcomes were reduction of TC, TG, LDL-C (p<0.05) and elevation of HDL-C (p<0.05) level. Also, coronary artery risk index (CRI) and atherogenic index (AI) were lowered (p<0.01). This study has confirmed risk lowering effect of CVDs, which are the major complications of MetS.
c) Reduction of apolipoprotein B-100
(c.1) In vivo
Dyslipidemia is one of the common insulin resistance complications of metabolic syndrome. It is characterized by elevated atherogenic lipid and lipoprotein profile, especially hepatic very low-density lipoprotein (VLDL) overproduction. Elevated hepatic VLDL secretion leads to increased plasma apolipoprotein B100 (apoB-100)-containing lipoprotein.
d) Regulation of mRNA expressions related to serum plasma metabolism
(d.1) In vivo
Aspergillus niger fermented Chenpi also was discovered to have hypolipidemic effects by modulating mRNA expressions involved with lipid-metabolism. CMPE 1%, FCMPE 0.3% and FCMPE 1% were applied to HFD mice for 13 weeks28. As a result, significant suppressions of those mRNA expressions were observed only in fermented Chenpi groups. Sterol regulatory element binding protein 1c (Srebp1c) mRNA expression in both FCMPE groups, fatty acid synthase (Fas) mRNA expression in 0.3% FCMPE group, and acetyl CoA carboxylase (Acc), carnitin palmitoyl transferase 1 (Cpt1) mRNA expression in 1% FCMPE group were all significantly reduced (p<0.05). These mRNAs are all related to hepatic lipogenesis and fatty acid oxidation. Also, expressions of sterol regulatory element binding protein 2 (Srebp2), HMG CoA reductase (Hmgr) and proprotein convertase subtilisin/kexin type 9 (Pcsk9), which are related to hepatic cholesterol homeostasis, were significantly reduced in FCMPE 0.3% and 1% group (p<0.05).
e) Regulation of biomarkers related to plasma lipid metabolism
(e.1) In vivo
CPW reversed abnormal changes in biomarkers, related to aurine and hypotaurine metabolism, fatty acid biosynthesis and arginine and proline metabolism37. 5-L-Glutamyl-taurine, an intermediate product of taurine metabolism which is related to oxidative stress reaction was significantly decreased after CPW treatment (p<0.05). Cis-4-Octenedioic acid and 2-octenedioic acid, the unsaturated fatty acids which increases in abnormal fatty acid metabolism situation, was also reduced by CPW (p<0.05). Additionally, 5-Aminopentanoic acid, a lysine degradation product, was decreased significantly (p<0.05).
3. Obesity
The overweight and obesity are the risk factors of HL, HTN, IR and T2DM60. Worldwide overweight currency is estimated about 2 billion, and one-third of them satisfies the criteria of obesity61. Since World Health Organization (WHO) has defined obesity as a global epidemic in 199662, the demand for effective treatments raised, as well as herbal therapy. The effect of Chenpi on obesity is analyzed below (Table 3).
a) Reduction of food efficiency ratio (FER)
(a.1) In vivo
CMPE 0.5% (241.9 mg/kg) applied to HFD rats34 and CMPE 2 g per 100 g diet to diabetic mice35 induced significant decrease of FER (p<0.05). Especially in CMPE 2 g group on the other hand, FER was significantly increased in RGZ group by 2.9-fold, suggesting greater weight gain efficiency. CMP powder 10% and 15% also reduced FER (p<0.05)30. Aureobasidium pullulans fermented CMPE and CMPE 0.1%, 0.5% each were administered to HFD rats, and FER was significantly reduced (p<0.05), except for CMPE 0.5% group39. As well, FCMPE processed by Aspergillus niger, which was found to contain naringenin, was administered to HFD mice28. FCMPE 0.3%, 1% and CMPE 1% all lowered FER in HFD mice (p<0.05).
b) Reduction of body weight, body mass index and waist circumference
(b.1) In vivo
Significant decrease in body weight gain was observed in CMPE 2 g per 100 g diet fed diabetic mice (p<0.05), whereas those in rosiglitazone (RGZ) group were markedly increased compared to both the control and CMPE groups35. As well, body weight was significantly reduced by CMPE 300 mg/kg twice daily administration (p<0.001)32. Daily feeding of CMP powder 15% had significant bodyweight reducing effect in HFD rats (p<0.05)30. Weight lowering effect of fermented Chenpi at HFD rats also have been proved. Aureobasidium pullulans fermented CMPE and CMPE 0.1%, 0.5% each were fed, and body weight of FCMPE 0.1%, 0.5% and CMPE 0.1% were significantly reduced (p<0.05)39. Especially FCMPE 0.5% group, which was the most effective, lost more than 40 g compared to control group. Aspergillus niger fermented CMPE 0.3%, 1% and CMPE 1% were applied, and both doses of FCMPE significantly reduced body weight (p<0.05)28. A clinical research about CMP also has been conducted. CMP juice extract administration to 118 adult patients of BMI over 23 kg/m2 resulted significant loss of body weight (p<0.0001)40. Several in vivo studies about CBP are also presented. CBPW 1.04 g/kg (p<0.05)36, CBPE 0.2% and 0.5% (p<0.05)37 led to significant body weight reduction in HFD rats.
(b.2) Clinical research
A clinical research, 4 weeks application of CMP juice extract to 118 adult patients of BMI over 23 kg/m2 resulted in reduction of BMI (p<0.0001) and waist circumference (p=0.0002)40.
c) Reduction of visceral adipose tissue
(c.1) In vivo
CMPE 0.5%34 and Aureobasidium pullulans fermented CMPE 0.5%39 significantly reduced weight of visceral adipose tissue (p<0.05). In addition, Aspergillus niger fermented CMPE 0.3% and 1% lowered epididymal fat weight and adipocyte size of epididymal fat (p<0.05) in HFD rats28. In diabetic mice, CMPE 2 g per 100 g diet significantly reduced total white adipose tissue (WAT) weight (p<0.05) and epididymal WAT weight35. Also in this case, total WAT weight of RGZ group was markedly increased compared to both the control and CMPE group. CMP powder 10% and 15% lowered liver, kidney and testis weight of HFD fed rats (p<0.05)30.
d) Suppression of TG biosynthesis
(d.1) In vitro
Glycerol 3-phosphate dehydrogenase (GPDH) uses NAD as a coenzyme, and transfers dihydroxyacetone phosphate into glycerol-3-phosphate63,64. It is usually activated in case of differentiation of preadipocyte into adipocyte. GPDH activity seems to be elevated in adipose tissue of obese subjects65. CMPE, Aureobasidium pullulans fermented CMPE and fermented citrus peel culture broth powder (FCB) 25 mg/mL suppressed GPDH activity in 3T3-L1 cell39.
e) Suppression of lipid accumulation
(e.1) In vitro
CMPE, Aureobasidium pullulans fermented CMPE and FCB 25 mg/mL lowered TG content in 3T3-L1 cell39. In 2014 study, CMPW and Citrus Unshiu Pericarpium Immaturus water extract (CMPIW), each 100 μg/ml, were administered to OP9 cell23. As a result, both significantly inhibited lipid accumulation and CMPIW was found out to be more effective than CMPW (p<0.01).
f) Stimulation of lipid excretion through feces
(f.1) In vivo
Fibrous element of Chenpi also has shown anti-obesitic effect. 1% albedo total dietary fiber (TDF), extracted by method of Prosky, was fed to Wistar-Hannover GALAS rats. As a result, weight of the cecum content and lipid content of feces were significantly reduced (p<0.05)31.
g) Suppressing adipogenesis
(g.1) In vitro
In 3T3-L1 cells, CMPE, Aureobasidium pullulans fermented CMPE and FCB 25, 50 mg/mL suppressed adipogenesis39.
h) Regulation of lipid metabolism
(h.1) In vitro
Adiponectin, which promotes insulin activity, is suppressed by inflammatory cytokines such as IL-6, tumor necrosis factor α (TNFα) and IFN-γ66. Decrease of adiponectin level was observed in hepatic steatosis and T2DM model (OP9 cell)67,68.
PPARγ, a transcription factor which is strongly expressed in adipose tissue, is involved in adipogenesis differentiation, carbohydrate, and lipid metabolism69. CMPW and CMPIW down regulated the protein expression of peroxisome-proliferator activated receptor γ2 (PPARγ2) and Adiponectin23. In addition, CMPI was found to have better lipid-lowering and PPARγ2 suppressing effect than CMP. CMPW 100 μg/ml suppressed protein expression of PPARγ2 in OP9 cell23. Cytolase is a compound of glycosidases removed from Aspergillus niger, which bioconverted CMP into aglycoside forms. In 3T3-L1 cells, Citrus unshiu with cytolase (CMPC) 0.5 mg/mL significantly reduced mRNA levels of CCAAT/Enhancer-binding Protein α (C/EBPα), SREBP1, protein expression of C/EBPα and PPARγ (p<0.05)27. It also significantly suppressed adipocyte differentiation (p<0.05), showing better effect than that of Sinetrol positive control group. In all CMPC, CMPW and CMPE 0.5 mg/mL groups, mRNA level of PPARγ was reduced, and glycerol secretion, which is involved in lipolysis, was increased (p<0.05).
(h.2) In vivo
Anti-obesitic activity related to lipase activity of Chenpi dietary fiber was evaluated. 1% albedo TDF extracted by method of Prosky significantly suppressed inhibition of pancreatic lipase activity in Wistar-Hannover GALAS rat (p<0.05)31. Also, CMPE 2 g per 100 g diet fed to diabetic mice for 6 weeks increased plasma adiponectin level35.
4. Hepatic steatosis
IR has strong correlation to hepatic steatosis, a previous phase of NAFLD70. Resistance to insulin activity on hepatic gluconeogenesis leads to an excessive lipid accumulation in the liver71. Susceptibility of IR and type 2 DM in patients with NAFLD has been studied72. The effect of Chenpi on hepatic steatosis is analyzed below (Table 4).
a) Reduction of liver weight and size
(a.1) In vivo
CMPE 2 g per 100 g diet fed to diabetic mice significantly reduced liver weight (p<0.05, p<0.01 each) and size35. CMPW 200 and 300 mg/kg significantly decreased liver and kidney weight (p<0.05) and size in STZ induced diabetic mice38.
b) Suppression of hepatic lipid accumulation
(b.1) In vivo
Various studies have shown reduction of hepatic lipid accumulation in liver. It was shown at CMPE 300 mg/kg in OVX rats33. Particularly, CMPE 2 g per 100 g diet administration to diabetic mice lowered hepatic lipid levels were in comparison to those in RGZ 0.001 g per 100 g diet group, which were conversely increased35. Similar results were shown at CMP powder 5%, 10%, 15%30 and Aspergillus niger fermented CMPE 0.3%, CMPE 1% (p<0.05)28 in HFD mice. CBPE 0.2%, 0.5% in HFD mice lowered lobule structure, micro steatosis and excessive lipid droplet accumulation in the liver, in both groups37. Also, 10% and 15% CMP powder in HFD rats resulted in reduction of hepatic total lipid level (p<0.05)30.
c) Reduction of hepatic lipid levels
(c.1) In vivo
CMPE 2 g per 100 g diet lowered hepatic TG, TC and FFA level in diabetic mice (p<0.05)35. Freeze dried Chenpi also had lipid lowering effect. Hepatic TC level was reduced by 10%, 15% freeze dried CMP medication, and hepatic TG level was reduced by 10% CMP powder medication30. In OVX rats, CMPE 100 and 300 mg/kg administration induced decreased of hepatic TC and TG level (p<0.05)33. In HFD mice CBPE 0.2%, 0.5% all reduced hepatic TG level, significantly (p<0.05)37. In addition, CBPE 0.5% apply lowered hepatic TC level (p<0.05)37.
d) Suppression of hepatic lipid synthesizing enzyme activity
(d.1) In vivo
CMPE 2 g per 100 g diet fed to diabetic mice resulted in down regulation of hepatic lipid regulating enzyme activities and mRNA expression35. Hepatic FAS, malic enzyme (ME) activities, which implies fatty acid synthesis, were significantly down-regulated, even compared to that of RGZ group (p<0.05). Activity of phosphatidate phosphohydrolase (PAP), related to TG synthesis, was down-regulated (p<0.05), and reverse effect was shown in RGZ group. The rate-limiting enzyme in cholesterol synthesis, m-RNA level of HMGR, was significantly lowered (p<0.05). Also, hepatic CMPT mRNA expression and fatty acid β-oxidation were significantly up-regulated (p<0.05).
Administration of 0.2% and 0.5% CBPE to HFD mice proved anti-hepatic oxidative stress effect36. In both groups, serum malondialdehyde (MDA) level was lowered (p<0.05) and hepatic glutathione reductase (GR) level was elevated (p<0.05). And in 0.5% group, hepatic MDA, and hepatic lipid peroxidation (LPO) level were reduced (p<0.05). Lastly, it upregulated hepatic mRNA expression of nuclear factor - like 2 (Nfr2) signaling genes and ameliorated inflammatory cytokines. Up-regulations of nuclear factor erythroid 2-related factor 2 (Nrf2) mRNA expressions in both groups (p<0.05) and peroxiredoxin (Prdx) and Nicotinamide Adenine Dinucleotide Phosphate Hydrogen quinone oxidoreductase (NQ-O1) mRNA expressions in 0.5% group (p<0.05) were observed.
e) Reduction of non-alcoholic fatty liver activity score
(e.1) In vivo
0.5% CBPE fed to HFD mice confirmed significantly lowered NAFLD activity score (NAS) (p<0.05).
5. Inflammation
Reports have proved the relation of inflammationin the pathogenesis of MetS associated disorder, T2DM73-76. In addition, it is known that chronic inflammation is closely related to T2DM and MetS77. The effect of Chenpi on inflammation is analyzed below (Table 5).
a) Reduction of tumor necrosis factor and interferon level
(a.1) In vivo
CMPE 2 g per 100 g diet was fed to diabetic mice, for 6 weeks, and RGZ was selected as positive control35. In conclusion, reduction of inflammatory biomarkers in blood and liver were observed, which indicate that CMPE attenuated diabetes-induced inflammatory responses. Plasma interleukin (IL-6), tumor necrosis factor-α (TNF-α) and IFN-γ level were significantly decreased (p<0.05). In addition, adiponectin (plasma anti-inflammatory) and IL-10 level were increased but RGZ group lowered them. Elevation of plasma proinflammatory cytokines such as interleukin-6 (IL-6), TNFα and interferon (IFN)-γ78-81, and a decrease of IL-10 is associated to T2DM82,83.
0.2% and 0.5% of CPBE fed to HFD mice confirmed inhibition of hepatic inflammatory factors, as well36. TNF-α, IL-6 and IL-1β mRNA levels were lowered in both groups (p<0.05). Especially, suppression of IL-1β activity was significantly better in CBPE groups, compared to positive control group (0.1% resveratrol).
b) Reduction of human monocyte chemoattractant protein-1 level
(b.1) In vivo
Especially, an inflammatory chemokine human monocyte chemoattractant protein-1 is linked to insulin resistance, leading to NAFLD78. CMPE 2 g per 100 g applied to HFD mice reduced plasma MCP-1 level and hepatic MCP-1 mRNA expression. However, RGZ group did not alter this pro-inflammatory marker in plasma and liver.
IV. Conclusion and Discussion
Recently, various in vitro, in vivo, and clinical studies have substantiated that Chenpi has beneficial effects against T2DM, HL, obesity, hepatic steatosis, and inflammation, resulting in amelioration of MetS. According to previous discussion in this article, Chenpi has effect on T2DM through glucose lowering, insulin secretion stimulation, glucose regulation, gluconeogenesis suppression, beta cell protection and anti-inflammatory activity. It exerts effect on HL through plasma lipid regulation, apolipoprotein reduction, plasma lipid metabolism regulation and preventing atherosclerosis. In aspects of obesity, Chenpi exerts decrease of FER, body weight, BMI, visceral adipose tissue, TG bio synthesis, lipid accumulation and adipogenesis. Lipid metabolism regulation and lipid excretion through feces are also included. Chenpi has also been substantiated hepatic steatosis ameliorating effect, by reduction of liver weight and size, hepatic lipid accumulation, hepatic lipid level, NAFLD activity score and suppression of hepatic lipid synthesizing activity.
Chenpi has effect of regulating qi (理氣), dissolving abscesses (散結), drying dampness (燥濕), relieving hiccup (止呃), suppressing cough (止咳), ameliorating diarreha (止瀉), resolving phlegm (化痰), removing food stagnation (導滯), eliminating phlegm (消痰), increaseing appetite (開胃), relieving strangury (通淋). It has been used in various symptoms, comprising vomiting, hiccup, lost of appetite, cough, sputum and dyspepsia84. It is included in various decotions for digestive symptoms and invigorants. Gamibojungikgi-tang85, gamiyukgunja-tang86, yukgunja -tang87, gamiyijin-tang88, gamigwakhyangjeonggi-san89 had been reported for their anti-obesitic effets. Also, bojungikgi-tang90 for its hypolipidemic effect, sopyung-tang91, gamiyukmijihwang-tang92 for their hypoglycemic effect, and saenggangeonbi-tang93,94 for its anti-fatty liver effect had been reported. All mentioned herbal decotions contains Chenpi as common herbal medicine. It implies possibility of Chenpi as treatment of various metabolic diseases. However, lack of clinical or reviewing researches so far built limits to prove the efficacy of Chenpi. Therefore, our research targeted the potentials of Chenpi for MetS treatment. Chenpi appears to be potential treatment of chronic metabolic disorders, as hypoglycemic, hypolipidemic, anti-obesitic, fatty liver-ameliorating and anti-inflammatory effects were broadly studied. On the basis of our research, we look forward to continuous studies and to prove applicability of Chenpi as Mets treatment, in clinical use.
There were some limitations on discussing effects of Chenpi on our research. First, every dose of Chenpi used in experiments were not quantified, so it was not enough to compare exact effect with same amount of experimental material. Second, there were some studies about effect of bioconversed Chenpis, claiming that anti-diabetic, anti-hyperlipidemic and anti-obesitic effect would be reinforced by bioconversion. Though, bioconversed flavonoids were not standardized due to all different mycotoxins used in fermentation, resulting in inexact comparison. Finally, more clinical studies about efficacy of Chenpi in above-mentioned conditions (diabetes, hyperlipidemia, obesity, hepatic steatosis and inflammation) should be required to provide evidence of clinical use.